EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access

Cardiac fibrosis: from mechanisms and models to medicines

Wenqiang Liu, Xuekun Wu, Wenshu Zeng, Mark Chandy, Joseph C Wu

Trends in Pharmacological Sciences · 2025-11 · 46 (11) · 1072-1090

DOI: 10.1016/j.tips.2025.07.016 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Trends in Pharmacological Sciences, 2025-11. Verfasst von Wenqiang Liu und 4 weiteren Autor:innen. Beteiligte Einrichtung: Stanford Cardiovascular Institute, Stanford University School of Medicine, Stanford, CA 94305, USA; Department of Medicine, Division of Cardiovascula…. Hauptthemen laut MEDLINE: Myocardium, Antifibrotic Agents, Heart Diseases. Die Arbeit wurde bisher 25-mal zitiert (Crossref) und nennt 119 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NHLBI NIH HHS, NIAID NIH HHS, American Heart Association-American Stroke Association.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Cardiac fibrosis is a hallmark of cardiovascular and systemic diseases that arises in diverse pathological contexts such as inflammation, metabolic stress, and mechanical overload. Despite its clinical relevance, no FDA-approved therapies directly target cardiac fibrotic remodeling, highlighting persistent challenges in disease organization, model fidelity, and translational strategy. Recent advances in human induced pluripotent stem cell (iPSC)-derived models, engineered heart tissues, and in vivo systems have uncovered new fibrotic drivers, including immune-stroma crosstalk, metabolic reprogramming, and mechanotransduction, that are reshaping therapeutic development. This review synthesizes emerging molecular mechanisms, experimental models, and preclinical and clinical investigations of antifibrotic agents. Distinct from previous reviews, we emphasize cross-contextual alignment to support the development of precision antifibrotic therapy for cardiac fibrosis.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

MyocardiumAntifibrotic AgentsHeart DiseasesHumansFibrosisAnimalsInduced Pluripotent Stem Cells

Stichwörter der Autor:innen

antifibrotic therapyfibroblast activation statesmultiscale platformsrepurposed drugstranslational models

Substanzen

Antifibrotic Agents

Autor:innen und Institutionen

  • Stanford Cardiovascular Institute, Stanford University School of Medicine, Stanford, CA 94305, USA; Department of Medicine, Division of Cardiovascular Medicine, Stanford University School of Medicine, Stanford, CA 94305…

Förderung

  • NHLBI NIH HHS
  • NIAID NIH HHS
  • American Heart Association-American Stroke Association
  • Stanford Maternal and Child Health Research Institute
  • National Institutes of Health
  • American Heart Association

Zitieren

APA

Liu, W., Wu, X., Zeng, W., Chandy, M., & Wu, J. C. (2025). Cardiac fibrosis: from mechanisms and models to medicines. Trends in Pharmacological Sciences, 46(11), 1072-1090. https://doi.org/10.1016/j.tips.2025.07.016

Vancouver

Liu W, Wu X, Zeng W, Chandy M, Wu JC. Cardiac fibrosis: from mechanisms and models to medicines. Trends in Pharmacological Sciences. 2025;46(11):1072-1090. doi:10.1016/j.tips.2025.07.016

BibTeX
@article{Liu2025,
  author = {Liu, Wenqiang and Wu, Xuekun and Zeng, Wenshu and Chandy, Mark and Wu, Joseph C},
  title = {Cardiac fibrosis: from mechanisms and models to medicines},
  journal = {Trends in Pharmacological Sciences},
  year = {2025},
  volume = {46},
  number = {11},
  pages = {1072--1090},
  doi = {10.1016/j.tips.2025.07.016}
}
Kostenlos starten →